Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2020-04-22 AGM Information
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Celon Pharma S.A. na dzień 19 maja 2020 roku wraz z projektami uchwał - Content (PL)
AGM Information Classification · 98% confidence The document text explicitly states that the Management Board ('Zarząd') is convening an Annual General Meeting ('Zwyczajne Walne Zgromadzenie') for May 19, 2020. It details the planned agenda ('Planowany porządek obrad'), which includes reviewing the 2019 annual report, approving financial statements, and voting on board members and remuneration policies. This content directly corresponds to the materials prepared for an AGM. Although it mentions that some reports are attached or will follow later, the primary purpose of this specific filing is the formal announcement and provision of materials for the AGM itself. Therefore, the classification is AGM Information (AGM-R).
2020-04-22 Polish
Rekomendacja Zarządu Spółki w sprawie podziału zysku za rok 2019 - Content (PL)
Notice of Dividend Amount Classification · 98% confidence The document text, written in Polish, explicitly details the management board's (Zarząd) recommendation to the Annual General Meeting (Zwyczajnemu Walnemu Zgromadzeniu) regarding the allocation of the net profit for 2019. Specifically, it allocates funds for increasing reserve capital and, crucially, sets aside PLN 3,600,000.00 for the payment of a dividend to shareholders (0.08 PLN per share), including the record date (June 2, 2020) and payment date (June 19, 2020). This content directly relates to the announcement of dividend amounts and details, matching the definition for 'Notice of Dividend Amount' (DIV). It is not a general AGM presentation (AGM-R) or a full annual report (10-K).
2020-04-21 Polish
Analiza wstępnych wyników badania klinicznego II fazy leku opartego na Esketaminie u pacjentów z depresją jednobiegunową - Content (PL)
Legal Proceedings Report Classification · 95% confidence The document is a formal announcement (Raport Bieżący) from a company (Celon Pharma S.A.) informing the public about the completion of an interim analysis of Phase II clinical trial results for a drug based on Esketamine. It details patient numbers, dosage groups, primary endpoints (MADRS scale), response rates, remission rates, safety data (adverse events), and dissociation scores (CADSS). This content is highly specific to clinical trial progress and results reporting, which falls under the scope of general regulatory announcements or potentially a specific type of regulatory filing, but given the context of reporting on clinical trial progress and initial results, it is best classified as a general Regulatory Filing (RNS) or potentially an announcement related to R&D/Product development, which is not explicitly listed. Since it is a formal, non-periodic report detailing specific operational/development milestones, and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), the most appropriate general category for specific, non-standard regulatory updates is RNS. The document is short and appears to be an official disclosure rather than the full scientific report itself.
2020-04-20 Polish
Podpisanie porozumienie ramowego z Siecią Badawczą ŁUKASIEWICZ dotyczącego rozpoczęcia wspólnego program rozwoju terapii przeciw COVID-19 - Content (PL)
Regulatory Filings Classification · 92% confidence The document text is a short announcement (1529 characters) written in Polish, referencing a prior current report ('raport bieżący 6/2020'). It details the signing of a framework agreement between Celon Pharma S.A. and Sieć Badawcza Łukasiewicz to commence a joint research program focused on COVID-19 therapeutics, including identifying therapeutic potential of known drugs and developing innovative molecules. It also mentions seeking strategic financial support for these research activities. This document is an announcement of a specific business development (a research partnership) rather than a full financial report (like 10-K or IR) or a standard regulatory filing fallback (RNS). Given the content focuses on strategic research and development activities, it aligns best with a general corporate announcement that doesn't fit the highly specific financial codes. However, since it is a specific announcement about a strategic partnership/research initiative, and not a standard financial report, it is best classified as a Regulatory Filing (RNS) as a general corporate event disclosure, or potentially a Legal/Contractual update, but RNS is the most appropriate general disclosure category when specific codes like 'LTR' (Legal Proceedings) or 'CAP' (Financing) don't perfectly apply to the core subject matter (R&D agreement). Given the context of Polish regulatory filings, these types of specific operational updates often fall under general disclosure rules. Since it is not a report announcement (RPA) but the content of the announcement itself, RNS is the best fit among the available options for a non-financial, non-management change disclosure.
2020-03-23 Polish
CELON_RAPORT_Y2019_Informacje_dodatkowe.pdf
Management Reports Classification · 95% confidence The document provides detailed management commentary, financial disclosures, notes on financial instruments, employment data, remuneration details, and information on legal proceedings and post-balance sheet events (including COVID-19 impact). It functions as the management's discussion and analysis section of a financial report, providing context to the financial statements. Given the depth of the analysis and the specific management-focused content, it is classified as a Management Report (MDA). FY 2019
2020-03-20 Polish
CELON_RAPORT_Y2019_WPROWADZENIE.pdf
Audit Report / Information Classification · 98% confidence The document is titled "Sprawozdanie finansowe Celon Pharma Spółka Akcyjna z siedzibą w Kiełpinie za rok obrotowy od 1 stycznia 2019 roku do 31 grudnia 2019 roku" (Financial Statement of Celon Pharma S.A. for the financial year from January 1, 2019, to December 31, 2019). It contains detailed sections on accounting policies, valuation methods for assets (intangibles, fixed assets, inventory, investments), liabilities, capital, and deferred taxes, covering a full fiscal year (2019). This content structure is characteristic of a comprehensive annual financial report, which aligns with the definition of a 10-K (Annual Report), even though the document is in Polish and likely filed under local regulations corresponding to the annual reporting requirement. Given the comprehensive nature and the full-year scope, the classification is Annual Report (10-K). FY 2019
2020-03-20 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.